311 related articles for article (PubMed ID: 33029680)
1. Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms.
Vijayvergia N; Dasari A
Curr Treat Options Oncol; 2020 Oct; 21(12):96. PubMed ID: 33029680
[TBL] [Abstract][Full Text] [Related]
2. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
3. Targeting the mTOR signaling pathway in neuroendocrine tumors.
Chan J; Kulke M
Curr Treat Options Oncol; 2014 Sep; 15(3):365-79. PubMed ID: 25092520
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin.
Basu B; Sirohi B; Corrie P
Endocr Relat Cancer; 2010 Mar; 17(1):R75-90. PubMed ID: 20008097
[TBL] [Abstract][Full Text] [Related]
5. The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors.
Cives M; Pelle' E; Quaresmini D; Mandriani B; Tucci M; Silvestris F
Curr Treat Options Oncol; 2019 Jul; 20(9):72. PubMed ID: 31346813
[TBL] [Abstract][Full Text] [Related]
6. [Neuroendocrine tumors: analysis of 252 cases].
Chi YH; Jiang WC; Du F; Sun YK; Song Y; Yang L; Zhou AP; Wang JW
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):67-70. PubMed ID: 23648305
[TBL] [Abstract][Full Text] [Related]
7. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.
Neychev V; Steinberg SM; Cottle-Delisle C; Merkel R; Nilubol N; Yao J; Meltzer P; Pacak K; Marx S; Kebebew E
BMJ Open; 2015 May; 5(5):e008248. PubMed ID: 25991462
[TBL] [Abstract][Full Text] [Related]
8. Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.
Hauser H; Gerson DS; Reidy-Lagunes D; Raj N
Curr Treat Options Oncol; 2019 Nov; 20(12):87. PubMed ID: 31776785
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
Cloyd JM; Konda B; Shah MH; Pawlik TM
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383
[TBL] [Abstract][Full Text] [Related]
10. Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors.
Dasanu CA; Majumder S; Gopal S; Stoica-Mustafa E; Trikudanathan G
Expert Opin Pharmacother; 2012 Mar; 13(4):461-71. PubMed ID: 22292707
[TBL] [Abstract][Full Text] [Related]
11. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies.
Ruggeri RM; Benevento E; De Cicco F; Fazzalari B; Guadagno E; Hasballa I; Tarsitano MG; Isidori AM; Colao A; Faggiano A;
J Endocrinol Invest; 2023 Feb; 46(2):213-234. PubMed ID: 36038743
[TBL] [Abstract][Full Text] [Related]
13. Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
Wolin EM
Chest; 2017 May; 151(5):1141-1146. PubMed ID: 27373769
[TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy of digestive neuroendocrine tumors].
Rougier P; Toma C; Fabri MC; Ducreux M
Ann Gastroenterol Hepatol (Paris); 1995; 31(2):117-20. PubMed ID: 7618833
[No Abstract] [Full Text] [Related]
15. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.
Ito T; Lee L; Jensen RT
Expert Opin Pharmacother; 2016 Nov; 17(16):2191-2205. PubMed ID: 27635672
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapy for advanced pancreatic neuroendocrine tumors: an update.
Reidy-Lagunes DL
J Natl Compr Canc Netw; 2012 Jun; 10(6):777-83. PubMed ID: 22679119
[TBL] [Abstract][Full Text] [Related]
17. Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic.
Rose DB; Nellesen D; Neary MP; Cai B
J Med Econ; 2017 Apr; 20(4):395-404. PubMed ID: 27981858
[TBL] [Abstract][Full Text] [Related]
18. Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?
Rodriguez-Freixinos V; Thawer A; Capdevila J; Ferone D; Singh S
Curr Oncol Rep; 2021 May; 23(7):80. PubMed ID: 33937962
[TBL] [Abstract][Full Text] [Related]
19. Recent Updates in the Management of Advanced Pancreatic Neuroendocrine Tumors.
Cho CM
Korean J Gastroenterol; 2019 Mar; 73(3):124-131. PubMed ID: 31013555
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy for advanced pancreatic neuroendocrine tumors.
Kulke MH
Semin Oncol; 2013 Feb; 40(1):75-83. PubMed ID: 23391115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
